37 results about "Infective Agent" patented technology

Methods for treating an ear condition in a subject, comprising topically administering to the ear of the subject in need thereof a composition comprising: (i) an anti-infective agent-loaded biodegradable polymer microspheres; and (ii) a thermoresponsive hydrogel.

Hygienic Hydrophilic coatings, hydrophilic coating formulations and wetting fluids that include an anti-infective agent.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and / or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and / or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

Described herein are compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and a nucleic acid sequence (e.g., mRNA) encoding at least one universal T-cell epitope (UTE), as well as compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope, and methods for using the compositions.

Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.

The present application generally relates to compounds, pharmaceutical compositions and method to treat a patient with malaria related disease or Plasmodium infection. Particularly the method compromises the step of administering a therapeutically effective amount of the disclosed compounds or compositions, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.

The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and / or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

Methods of generating memory T cells in vitro are provided. The methods include culturing a population of T cells with a population of antigen-loaded dendritic cells for at least about 28-48 days in a culture medium and isolating memory T cells (such as CD4+ or CD8+ memory T cells) from the culture. Methods of treating a subject with cancer or infectious disease are also provided. The methods include administering to the subject memory T cells generated by the methods described herein, where the antigen-loaded dendritic cells are loaded with an antigen expressed by the cancer or the infectious agent causing the disease. Also provided are methods of identifying T cell receptors that specifically bind to an antigen recognized by a memory T cell, which include producing a population of memory T cells recognizing an antigen as described herein, and identifying the T cell receptor expressed by the memory T cells.

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and / or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The present invention relates to a magnetic anisotropic material, in the form of magnetic elongated elements, preferably superparamagnetic nanochains, for use in the disruption of a bacterial biofilm and / or in the sensitization of bacterial colonies to antibiotic treatment, the non-therapeutical use of said magnetic anisotropic material for disrupting a bacterial biofilm and / or sensitizing bacterial colonies present on a surface, on and / or within a medical device, in pipes, in conducts, and / or in a liquid, a biofilm disrupting and / or sensitizing composition comprising said magnetic anisotropic material and at least one antibacterial agent, said biofilm disrupting and / or sensitizing composition for use in the treatment of a bacterial infection or infestation involving biofilm formation, the non-therapeutical use of said composition as an anti-infective agent, preferably for the disinfection of a surface, a medical device, pipes, and / or conducts, or for purification of a liquid, and an in vitro or ex vivo method for disrupting a bacterial biofilm and / or sensitizing bacterial colonies to antibiotic treatment, wherein it comprises a step of applying an oscillating or rotating magnetic field to a magnetic anisotropic material.

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and / or into the wound of a patient.

Embodiments of the present disclosure are directed to systems and methods for collection and analysis of environmental air dust (EAD) within an individually ventilated cage rack (IVR) environment for detecting pathogens. The method includes collection of an EAD sample by a collection media, isolation of a plurality of nucleic acids (e.g., RNA and / or DNA) representative of one or more infectious agents from the EAD sample, optional reverse transcription of RNA to cDNA if the isolated nucleic acids contain RNA, amplification of the cDNA and / or DNA (e.g., by polymerase chain reaction (PCR)), and assay interpretation. Optionally, the EAD sample may be analyzed with one or more other sample types (e.g., fecal pellets, oral swabs, body swabs, tissue, etc.) to improve detection of low-copy organisms.

Provided are a Lactobacillus plantarum against Helicobacter pylori infection and the use thereof. The Lactobacillus plantarum against Helicobacter pylori infection is named Lactobacillus plantarum Lp05 and was deposited in the China General Microbiological Culture Collection Center on 9 Oct. 2021, with the deposit number CGMCC No. 23547. Further provided are a method for culturing the Lactobacillus plantarum against Helicobacter pylori infection and a product for inhibiting Helicobacter pylori infection. The Lactobacillus plantarum against Helicobacter pylori infection of the present application has good gastric acid resistance, inhibits the proliferation of Helicobacter pylori, and reduces the adhesion effect of Helicobacter pylori to gastric epithelial cells, thereby creating conditions for the eradication of Helicobacter pylori. The product for inhibiting Helicobacter pylori infection does not cause adverse reactions nor drug resistance of pathogenic bacteria.

The present disclosure relates to methods for assessing host DNA damage in samples exposed to infectious agents using antimicrobial-modified comet assay. The disclosure further relates to a modified comet assay configured to assess DNA damage while eliminating interference caused by infectious agents. The methods extend conventional comet assay use beyond chemical genotoxin screening to infection related damage profiling and quality controlled antimicrobial testing.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. 20 24 20 45 59 01 J ul 2 02 4 2 0 2 4 2 0 4 5 5 9 0 1 J u l 2 0 2 4

Metal nanoparticle agglomerates in various forms may be utilized to promote infection control. Antiseptic substrates may comprise a base substrate and metal nanoparticle agglomerates adhered thereto. Metal nanoparticle agglomerates upon the antiseptic substrates may be contacted with a skin penetration, a skin injury, a burn, a site to be subjected to a skin penetration, or an active skin infection to provide infection control against at least one infective agent. The antiseptic substrates may also facilitate water purification in some cases. Antiseptic fluid formulations comprising a fluid medium having metal nanoparticle agglomerates dispersed therein may be configured for topical or oral use and may similarly afford infection control. Creams, ointments, balms, salves, gels, and liquids or liquid suspensions containing metal nanoparticle agglomerates may be effective for promoting infection control and / or for treating an active infection.

A composition is disclosed that includes a chelating polymer including a first monomer unit and a second monomer unit polymerized by a reversible addition-fragmentation chain transfer mechanism using an addition-fragmentation chain transfer agent, and an anti-infective agent. The composition can be used to treat a bacterial infection or to reduce bacterial resistance to the anti-infective agent in a subject.

The invention discloses a method for screening fat key genes through whole genome knockout, and relates to the technical field of biology. According to the invention, a whole genome knockout system suitable for chicken preadipocyte lines (ICP) is established based on a strategy of improving lentivirus infection efficiency by a cationic co-infection agent, and lipid droplet phenotype screening is carried out in combination with flow cytometry SSC signals, so that key genes influencing fat deposition can be efficiently and systematically screened; and a new technical platform is provided for poultry fat metabolism research and low-fat breeding. Functional verification is performed on the CYP46A1 gene screened based on the system, and results show that after the gene is knocked out, lipid droplet accumulation of chicken preadipocytes is remarkably reduced, expression of lipid metabolism key genes is reduced, and the effect of the CYP46A1 gene in fat deposition regulation is defined.

Flow cytometry is used for diagnosis of infectious diseases by an analysis of cell mediated immune responses to specific infective agent antigens. Apparatus and methods of advanced flow cytometry are utilized to detect cell mediated immune responses to the presence of specific antigens from infective agents, such as bacteria, protozoa, viruses, helminth, prions. In some embodiments, methods as provided herein can be utilized in vitro to diagnose multiple infections within individuals.

To provide a compound having antibacterial activity. [Solution] The present invention relates to a novel oxazolidinone (formula I) having ring A characterized by a monocyclic, bicyclic, or spirocyclic substituent containing nitrogen. The present invention relates to TIFF2026092059000321.tif3764 or pharmaceutically acceptable salts thereof, their preparations, and their use alone or in combination with other anti-infective agents as drugs for treating Mycobacterium tuberculosis and other microbial infections. The present invention generally relates to compounds having antibacterial activity, more specifically, anti-tuberculosis properties. In particular, the present invention relates to substituted phenyloxazolidinone compounds useful for treating tuberculosis in patients requiring treatment for tuberculosis.

This invention provides an endothelial glycocalyx-protective perfusion solution composition, kit, and application for isolated lung perfusion. The composition comprises an organ flushing solution, a basal perfusion solution, and an endothelial glycocalyx protectant. The organ flushing solution includes dextran 40, electrolytes, buffer solutions, anticoagulants, and vasodilators. The basal perfusion solution includes albumin, dextran 40, electrolytes, glucose, buffer salts, anticoagulants, anti-inflammatory agents, anti-infective agents, and vasodilators. This invention uses the basal perfusion solution as the main component, adding an endothelial glycocalyx protectant to form a composite perfusion system. This system is used to inhibit or reduce the degradation and shedding of pulmonary vascular endothelial glycocalyx, maintain structural stability, reduce the risk of perfusion-related pulmonary edema and inflammatory damage, thereby improving the maintenance effect of isolated lung function. The product can be designed as a kit.

Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided.

The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of infectious diseases or in the treatment of diseases caused by Cryptosporidium.

A controlled release, antimicrobial gel for the treatment of vaginal infections, comprises a muco-adhesive gel matrix containing one or more anti-infective agents bound to said matrix and effective for the treatment of vaginal infections and capable of pH dependent delivery of said one or more anti-infective agents as a single application to the vaginal cavity over a period of 3 days, while the muco-adhesive gel matrix remains bound to the vaginal epithelia. The preferred anti-infective agents are thymol and carvacrol in combination. The antimicrobial gel is biocidal against biofilms formed by the causative agents of bacterial vaginosis, trichomoniasis and candidiasis. The antimicrobial gel is effective for achieving sustained delivery of the anti-infective agents to the vaginal cavity at a therapeutically efficacious dose from a single application of the gel for the treatment and prevention, and prevention of recurrence, of bacterial vaginosis, trichomoniasis and candidiasis.

The invention relates to a molecular system comprising: (i) at least one dynamic constitutional framework (DCF) comprising a plurality of cores and a plurality of connectors, (ii) a plurality of functional heads, (iii) at least one pillararene and, optionally, (iv) at least one anti-infective agent; wherein each of the anti-infective agents is hosted in one of the pillararenes; wherein the cores, connectors, functional heads, and pillararenes are covalently bound together by reversible bonds; and wherein each of the cores is covalently bound to at least three from the connectors, functional heads and pillararenes. The invention also relates to a pharmaceutical composition or medicament comprising the molecular system. The invention also relates to the molecular system for use in the treatment of an infectious disease such as a bacterial disease, preferably a disease caused by Acinetobacter baumannii bacteria.